Accumetrics' Plavix prognostic:
This article was originally published in Clinica
Executive Summary
Accumetrics has received US FDA clearance to market its VerifyNow P2Y12 blood test for determining a patient's response to Plavix (clopidogrel) - a drug used by almost 10 million patients in the US to prevent heart attack or stroke. According to the San Diego, California-based firm, some 5-30% of patients do not respond adequately to the drug. The easy-to-perform test, which provides results in less than 15 minutes, works by measuring the inhibiting effect of Plavix on platelets - blood cells primarily responsible for clotting. The test can also be used to assess a patient's clotting function prior to surgery. The company also markets VerifyNow tests for aspirin and GP IIb/IIIa inhibitors.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.